Skip to main content
Clinical Trials/NCT00567515
NCT00567515
Completed
Phase 2

Safety and Effectiveness of Left Atrial Appendage Occlusion

AtriCure, Inc.1 site in 1 country41 target enrollmentSeptember 2007

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
AtriCure, Inc.
Enrollment
41
Locations
1
Primary Endpoint
Safety - Device related complications
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This study is to evaluate acute and long-term safety and effectiveness of Left atrial appendage occlusion (LAA)with the AtriCure LAA Occlusion System. This device will be applied in patients with atrial fibrillation (AF), paroxysmal, persistent and permanent, undergoing cardiac surgery with a concomitant Maze/Ablation procedure.

Registry
clinicaltrials.gov
Start Date
September 2007
End Date
November 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Documented history (paroxysmal, persistent or permanent) of AF \[one episode within the last 12 months of enrollment\]
  • Elective Maze procedure
  • Suitable anatomy
  • Able and willing to sign informed consent
  • Age over 18 years

Exclusion Criteria

  • Patient from Intensive Care Unit with either:
  • intra-venous catecholamines
  • cardiac index \<1.8 l/min.
  • Reoperative Cardiac Surgery
  • Systemic or Inflammatory disease
  • Recent myocardial infarction (\< 21 days)
  • History of pericarditis
  • Patient taking part in any other device or drug study
  • Patient with known sensitivity or allergy to any of the device components

Outcomes

Primary Outcomes

Safety - Device related complications

Time Frame: 30 days

Efficacy - Occlusion of the LAA

Time Frame: 6 months

Study Sites (1)

Loading locations...

Similar Trials